Press release content from Business Wire. The AP news staff was not involved in its creation.
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine
January 26, 2021 GMT
NEW YORK & AMSTERDAM (BUSINESS WIRE) Jan 26, 2021
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company’s co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.
(1)
Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company s co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.